Morning Alert: aTyr Pharma Inc. (NASDAQ:LIFE), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Orange SA (ADR) (NYSE:ORAN), Gilead Sciences Inc. (NASDAQ:GILD)

aTyr Pharma Inc. (NASDAQ:LIFE) belongs to Healthcare sector. Its weekly performance is 11.34%. On last trading day company shares ended up $18.36. aTyr Pharma Inc. (NASDAQ:LIFE) distance from 50-day simple moving average (SMA50) is -13.98%. On 29 June, aTyr Pharma Inc. (NASDAQ:LIFE) announced that it has been added to the Russell 2000®, Russell 3000® and Russell Global Indexes as part of Russell Investments’ annual reconstitution that took place after market close.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) shares advanced 1.13% in last trading session and ended the day at $9.81. KERX Gross Margin is 50.00% and its return on assets is -86.80%. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) quarterly performance is -21.01%. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)‘s stock had its “buy” rating restated by stock analysts at MLV & Co. in a report issued on Thursday.

On 10 July, Orange SA (ADR) (NYSE:ORAN) shares advanced 8.30% and was closed at $16.05. ORAN EPS growth in last 5 year was -17.70%. Orange SA (ADR) (NYSE:ORAN) year to date (YTD) performance is -2.40%. Orange SA (ADR) (NYSE:ORAN) said that, it will pay its former Israeli branch Partner Communications Ltd €5 million ($5.58 million US) after the two dissolved their relationship earlier this year.

Gilead Sciences Inc. (NASDAQ:GILD) ended the last trading day at $113.74. Company weekly volatility is calculated as 1.91% and price to cash ratio as 14.80. Gilead Sciences Inc. (NASDAQ:GILD) showed a weekly performance of -1.13%.On 1 July, Gilead Sciences Inc. (NASDAQ:GILD) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older.

Leave a Reply

Your email address will not be published. Required fields are marked *